Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Ugeskrift for Laeger|September 2, 2024
Tue Wenzel Kragstrup, Kristine Jagd Ottosen, Line Uhrenholt, et al.
Rheumatology International|April 1, 2022
Isolation in patients with inflammatory rheumatic diseases during COVID-19 pandemic compared to healthy individuals: a questionnaire surveyTobias Eschricht Eriksen, Wilfred K H Dinesen, Line Uhrenholt, et al.
BMJ Open|July 12, 2019
Dosage reduction and discontinuation of biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis: protocol for a pragmatic, randomised controlled trial (the BIOlogical Dose OPTimisation (BIODOPT) trial)Line Uhrenholt, Annette Schlemmer, Ellen-Margrethe Hauge, et al.
British Journal of Clinical Pharmacology|June 5, 2023
Predicting successful biologics tapering in patients with inflammatory arthritis: Secondary analyses based on the BIOlogical Dose OPTimisation (BIODOPT) trialLine Uhrenholt, Kirsten Duch, Robin Christensen, et al.
Ugeskrift for Laeger|June 12, 2018
[Acute abdominal vasculitis in rheumatic diseases]Line Uhrenholt, Lars S Jensen, Thomas S Jakobsen, et al.
Rheumatology (Oxford, England)|December 28, 2020
Incidence and severeness of COVID-19 hospitalization in patients with inflammatory rheumatic disease: a nationwide cohort study from DenmarkRené Cordtz, Jesper Lindhardsen, Bolette G Soussi, et al.
Rheumatology (Oxford, England)|December 5, 2021
Risk of flare after tapering or withdrawal of biologic/targeted synthetic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis or axial spondyloarthritis: a systematic review and meta-analysisLine Uhrenholt, Robin Christensen, Wilfred K H Dinesen, et al.
Lupus|November 1, 2021
Patient-reported outcome measures in systemic lupus erythematosus by a web-based application: A randomized, crossover, agreement studyLine Uhrenholt, Simone Høstgaard, Julie F Pedersen, et al.
EULAR Rheumatology Open|June 29, 2026
Biological tapering is cost-effective in patients with inflammatory arthritis in the biosimilar era: secondary analyses on the randomised BIODOPT trialLine Uhrenholt, Mads Engell Refstrup Sørensen, Jan Sørensen, et al.
Rheumatology International|July 23, 2024
Exploring TNFi drug-levels and anti-drug antibodies during tapering among patients with inflammatory arthritis: secondary analyses from the randomised BIODOPT trialLine Uhrenholt, Mads E R Sørensen, Karen B Lauridsen, et al.
Pageof 2